ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Response Criteria"

  • Abstract Number: 0075 • ACR Convergence 2024

    Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis

    Darshini Ganatra1, Omar Cruz Correa1, Ameth Garrido2, Starlee Lively3, Rohan Apurva Machhar4, Remy Pollock5, Mohit Kapoor6 and Dafna Gladman7, 1University Health Network, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3UHN, Toronto, Canada, 4Novartis, Mississauga, ON, Canada, 5Pfizer, Toronto, ON, Canada, 6Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis linked to psoriasis, a chronic skin and nail disease. PsA is a progressive joint disease…
  • Abstract Number: 0222 • ACR Convergence 2024

    The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound

    Ricardo Sabido-Sauri1, Seyyid Bilal Acikgoz2, Ummugulsum Gazel1, Ozun Bayindir Tsechelidis3, Sylvia Sangwa4, Catherine Ivory5, Elliot Hepworth1 and Sibel Aydin6, 1University of Ottawa, Ottawa, ON, Canada, 2University of Ottawa, Rheumatology, Ottawa, ON, Canada, 3Ottawa University, Ottawa, ON, Canada, 4The Ottawa Hospital Research Institute, Ottawa, Canada, 5The Ottawa Hospital, Ottawa, ON, Canada, 6University of Ottawa - Ottawa, Ottawa, ON, Canada

    Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…
  • Abstract Number: 0309 • ACR Convergence 2024

    Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis

    Omar Hamdan1, Roa'a Alshajrawi1, Qais Mussa1, Yazeed Alajlouni1, Yazan Dabbah1, Rawan Fratekh1, Yousef Al-Mabrouk2, Shatha Al-Mabrok2 and Ahmad A. Toubasi1, 1University of Jordan, Amman, Jordan, 2Mansoura University, Al Mansoura, Egypt

    Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…
  • Abstract Number: 0636 • ACR Convergence 2024

    Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)

    Danielle Egypto1, Edgard Reis Neto2, Guilherme Carlesso3, Luis Andrade4, Luiz Moura3, Debora Calderaro5 and Emília Sato6, and Emília Inoue Sato; Edgar Torres dos Reis Neto., 1Federal University of Paraiba, JOÃO PESSOA, Paraiba, Brazil, 2Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil, 3Federal University of São Paulo, São Paulo, SP, Brazil, 4Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, SP, Brazil, 5Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 6Universidade Federal de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: LN occurrs in 50 to 75 percent of SLE patients and is associated with a significant morbimortality. LN presents distinct severity, with frequent flares…
  • Abstract Number: 1162 • ACR Convergence 2024

    Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom

    Xia Lyu1, Patrick Gordon2, Harsha Gunawardena3, Neil McHugh4, Sarah Tansley4, Athiveeraramapandian Prabu5, Peter Lanyon6, James Miller7, Voon Ong8, Anthony Isaacs9, Chee-Seng Yee10, Caroline Cotton11, Patrick Kiely12, Eleni Stathopoulou13, James Taylor14, Rachel Jeffery14, Anurag Bharadwaj15, James Lilleker16, Janine Lamb17 and hector Chinoy18, and MYOPROSP consortium, 1Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), 2nhs, London, United Kingdom, 3North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bath, United Kingdom, 4University of Bath, Bath, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 6Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 7Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, 8University College London, London, England, United Kingdom, 9Department of Rheumatology, London North West University Healthcare NHS Trust, London, United Kingdom, 10Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom, 11Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, 12Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom, 13Department of Rheumatology, Solihull Hospital, University Hospitals of Birmingham NHS FT, Birmingham, United Kingdom, 14Department of Rheumatology, Northampton General Hospital, Northampton General Hospital NHS Trust, Northampton, United Kingdom, 151Basildon University Hospital, Mid & South Essex NHS Foundation Trust, Rheumatology, Basildon, United Kingdom, Basildon, United Kingdom, 16Northern Care Alliance NHS Trust, Salford, United Kingdom, 17University of Manchester, UK, Manchester, United Kingdom, 18The University of Manchester, Manchester, United Kingdom

    Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…
  • Abstract Number: 1341 • ACR Convergence 2024

    Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis

    Santiago Dans Caballero1, Marta Rojas Giménez2, Clementina López Medina3, Andrea Cid Chaves2, Mónica Rico-Muñoz3, mitndbaim aelohim parra Moreno2 and Alejandro Escudero-Contreras4, 1Reina Sofia University Hospital, Lebrija, Andalucia, Spain, 2Reina Sofia University Hospital, Cordoba, Andalucia, Spain, 3Reina Sofia University Hospital, Cordoba, Spain, 4Reina Sofia University Hospital, Córdoba, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…
  • Abstract Number: 1642 • ACR Convergence 2024

    A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis

    Andrea Fava1, Andrew Concoff2, Tyler O'Malley3, Sepehr Taghavi4, Touba Warsi4, Sudha Kumar4, Christine Schleif4 and Michelle Petri5, 1Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Vista, CA, 4Exagen, Carlsbad, CA, 5Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
  • Abstract Number: 2034 • ACR Convergence 2024

    Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease

    Anne Dupont1, Clairelyne Dupin2, Esther Ebstein1, Marine Forien1, Sébastien Ottaviani1, Pierre Le Guen2, Quentin Philippot2, Raphaël Borie2, Bruno Crestani3, Philippe Dieudé1 and Pierre-Antoine Juge4, 1Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, 2National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, France, 3National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, 4Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA

    Background/Purpose: Interstitial lung diseases (ILD) are severe manifestations of systemic autoimmune diseases (SARD) that are associated with an increased mortality. Although the primary endpoint was not…
  • Abstract Number: 2093 • ACR Convergence 2024

    Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial

    Christopher Swearingen1, Yusuf Yazici2, Jeyanesh Tambiah3 and Philip G Conaghan4, 1Biosplice Therapeutics, Inc, San Diego, CA, 2NYU Grossman School of Medicine, La Jolla, CA, 3Biosplice Therapeutics Inc., San Diego, CA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways, demonstrated beneficial effects on clinical and radiographic outcomes in previous knee…
  • Abstract Number: 2575 • ACR Convergence 2024

    Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?

    Paola Vidal1, Javier Narvaez-García2, Francesc-Xavier Fulladosa2, Francesca Mitjavila2, olga Capdevila2, Pol Maymó3, Judith Palacios4 and Joan Miquel Nolla2, 1Hospital Universtiario de Bellvitge, Barcelona, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario de Bellvitge., Barcelona, Spain, 4Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain

    Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
  • Abstract Number: 2674 • ACR Convergence 2024

    Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States

    christina Charles-Schoeman1, Patrick Zueger2, Erin Blondell2, Siran Fang2, Yi Peng2, Manish Jain3 and John Tesser4, 1UCLA Medical Center, Santa Monica, CA, 2AbbVie Inc, North Chicago, IL, 3Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, 4Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ

    Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…
  • Abstract Number: 2486 • ACR Convergence 2023

    Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?

    Ewa Olech1 and Joan Merrill2, 1IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
  • Abstract Number: 2551 • ACR Convergence 2023

    Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis

    Ioannis Parodis1, Julius Lindblom1, Roger A. Levy2, Margherita Zen3, Nursen Cetrez1, Alvaro Gomez4, Shereen Oon5, Christine Henning6, Munther Khamashta7, Holly A. Quasny8, Deven Chauhan9, Anca Askanase10, Ronald van Vollenhoven11 and Mandana Nikpour12, 1Karolinska Institutet, Stockholm, Sweden, 2GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 3University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, 4Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 5University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, 6GlaxoSmithKline, US Medical Affairs, Durham, NC, 7GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, 8GlaxoSmithKline, Research & Development, Durham, NC, 9GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 10Columbia University Medical Center, New York, NY, 11Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, 12The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
  • Abstract Number: 0459 • ACR Convergence 2023

    Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial

    Ronald van Vollenhoven1, Vibeke Strand2, Tsutomu Takeuchi3, Nilmo Chávez4, Pablo Mannucci Walter5, Attul Singhal6, Jerzy Swierkot7, Nasser Khan8, Xianwei Bu9, Yihan Li9, Sara Penn9, Heidi Camp9 and Jacob Aelion10, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Stanford University, Portola Valley, CA, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala, 5Aprillus Asistencia e Investigación, Buenos Aires, Argentina, 6Southwest Rheumatology Research Group, Dallas, TX, 7Department of Rheumatology and Internal Medicine, Wrocław Medical Hospital, Wrocław, Poland, 8Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, 9AbbVie, Inc., North Chicago, IL, 10West Tennessee Research Institute, Jackson, TN

    Background/Purpose: To evaluate the efficacy and safety of upadacitinib (UPA) monotherapy vs MTX monotherapy over 5 yrs among MTX-naïve patients with moderately to severely active…
  • Abstract Number: 0507 • ACR Convergence 2023

    The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis

    Antoni Chan and NiSoe Nwe, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom

    Background/Purpose: Patient-reported outcome measures (PROMs) are important tools for evaluating disease activity, functional status, and quality of life in patients with psoriatic arthritis (PsA). The…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology